An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 23 Apr 2015
At a glance
- Drugs Ofatumumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Genmab; GlaxoSmithKline
- 20 Apr 2015 Status changed from completed to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 26 Nov 2006 New trial record.